Andrology-Open Access
Open Access
ISSN: 2167-0250
+44 1300 500008
ISSN: 2167-0250
+44 1300 500008
Jerzy Jankun, PhD
Editor-in-Chief
Professor, Director
The University of Toledo, USA
Dr. Jerzy Jankun is the founding Director of Urology Research Center and Professor at Department of Urology, at Health Science Campus of University of Toledo. URC scientific research interest concentrates on proteolysis and different cancers and other diseases. Inhibition of photolytic activity reduce cancer induced angiogenesis and consequently tumor growth. Additionally inhibitors of proteolysis can reduce cancer spread. Special interest includes modified proteins to be used in therapy. That includes plasminogen activator type 1 with very long half-life (VLHL PAI-1) and modified human lipoxygenase.In the past laboratory explored photodynamic therapy to eradicate prostate and other cancers using small molecular weight photosensitizers and sensitizers conjugated with antibodies in targeted photodynamic cancer therapy (PDT). Dr. Jerzy Jankun’s research interest concentrates on proteolysis and different cancers and other diseases. Inhibition of photolytic activity reduce cancer induced angiogenesis and consequently tumor growth